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1. Introduction
This chapter is an overview of the subject starting from the 
early landmark achievements, and includes papers, extended 
articles, reviews and books. Heparin and LMWHs are widely used 
for the prevention and treatment of thrombotic events by inhibiting 
antithrombin III (AT) and factor Xa through a specific oligosaccharide 
binding sequence (ATBR) present in only one third of unfractionated 
heparin chains as has been well-documented in two recent reviews 
[1,2]. Heparin, the most negatively charged biopolymer has an average 
of four negative charges for each disaccharide unit, can interact with 
a wide range of proteins, with interactions that exhibit a range of 
specificities [3] and induce several associated biological activities. 
These involve plasma or tissue proteins such as heparin cofactor II 
(HCII), tissue factor plasminogen inhibitor (TFPI), lipoproteinlipase, 
growth factors and heparanase. Interestingly, when a heparin 
ATIII-no-affinity fraction was added to normal plasma containing 
heparin, a marked increase in anti-factor Xa activity was observed, 
presumably due to the displacement of heparin with affinity for 
ATIII from binding plasma proteins [4].
2. Heparin and low molecular weight heparins (LMWH)
2.1. Anti-inflammatory, cardiovascular and tissue protection activities
The early reports of the beneficial effects of heparin in 
inflammation were attributed to the heparin binding and inhibition 
of chemokines, complement, growth and angiogenic factors, as 
reviewed recently [1,5,6,7]. Heparin can also bind to adhesion 
mediators expressed during inflammation, such as selectins, 
integrins and their receptors [8,9]. Tissue protection and repair were 
observed after heparin was inhaled to treat hot smoke inhalation 
injury in human fire survivors [5]. Topical, ophthalmic and 
parenteral formulations were also used to treat burns and lesions 
[10]. In low doses, heparin showed activity in several experimental 
models of inflammation as well as in the treatment of human 
chronic pulmonary diseases, by inhalation, or topically in allergic 
rhinitis [5]. Under various experimental and clinical conditions, such 
as oedema formation and pulmonary hypertension, heparin reduces 
leucocyte recruitment at the site of injury or inflammation stimuli, 
down-regulating cytokines, TNF-, endotoxins and inhibiting human 
leukocyte elastase (HLE), as well as heparanase [5]. In response 
to vascular injuries, excessive repair by artery smooth muscle 
cells (SMC) can induce vascular disorders such as restenosis and 
hypoxy-pulmonary hypertension. SMC proliferation was inhibited 
by heparin in tissue culture and in rat, and rabbit injury models 
K E Y W O R D S
Non-anticoagulant
Heparins
Inflammation
Cancer
Neuroprotection
A B S T R A C T
The aim of this chapter is to provide an overview of non-anticoagulant effects of heparins and their potential 
use in new therapeutic applications. Heparin and heparin derivatives have been tested in inflammatory, 
pulmonary and reproductive diseases, in cardiovascular, nephro- and neuro-tissue protection and repair, 
but also as agents against angiogenesis, atheroschlerosis, metastasis, protozoa and viruses. Targeting 
and inhibition of specific mediators involved in the inflammatory process, promoting some of the above 
mentioned pathologies, are reported along with recent studies of heparin conjugates and oral delivery 
systems. Some reports from the institute of the authors, such as those devoted to glycol-split heparins are 
also included. Among the members and derivatives of this class, several are undergoing clinical trials as 
antimetastatic and antimalarial agents and for the treatment of labour pain and severe hereditary anaemia. 
Other heparins, whose therapeutic targets are non-anticoagulant such as nephropathies, retinopathies and 
cystic fibrosis are also under investigation.
© 2016 Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license 
(http://creativecommons.org/licenses/by-nc-nd/4.0/)
Old and new applications of non-anticoagulant heparin
Giuseppe Cassinelli and Annamaria Naggi*
Istituto di Ricerche Chimiche e Biochimiche G Ronzoni, Milan, Italy
* Corresponding author at: Istituto di Ricerche Chimiche e Biochimiche G. Ronzoni, 
Milan, Italy
 E-mail address: naggi@ronzoni.it (A. Naggi).
0167-5273/© 2016 Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
 G. Cassinelli and A. Naggi / International Journal of Cardiology 212S1 (2016) S14–S21 S15
[12]. A recent systematic review with meta-analysis showed the 
beneficial effects of heparin treatment in asthmatic patients [13]. In 
normal subjects, heparin can inhibit reactive oxygen species (ROS) 
generation [14], supporting the observed cardiovascular protective 
effects, and also increases nitric oxide bioavailability through the 
release of vessel immobilized myeloperoxidase [15]. The role of 
neutrophil elastase, a highly aggressive endopeptidase, seems 
to be crucial and is provoked by imbalances of natural inhibitors 
leading to degradation of connective and tissue components as 
observed in emphysema, cystic fibrosis, rheumatoid arthritis, 
psoriasis, perodontitis, mucopolysaccharidosis, wound healing and 
tumour invasion. Elastase can be inhibited “in vitro” by heparin and 
derivatives [16–18] as well as in emphysema experimental models 
[19].
2.2. Heparanase inhibition: implication in various pathologies
Heparin can also inhibit the endo--D (1-4) glucuronidase, 
heparanase [20,21] that through cleavage of HS chains of heparan 
sulfate proteoglycans affects their functions, the integrity and 
functional state of the extracellular matrix (ECM) and basement 
membrane of vessel walls. Owing to the ubiquitous presence and 
multiple roles of HS, such as growth factor storage and activity, 
cytokines, chemokines and heparanase degrading activity, it is 
involved in several pathological conditions including inflammation, 
amyloidosis, diabetic and glomerular nephropathies, cancer meta-
stasis and angiogenesis. Overexpression and enhanced local activity 
of heparanase were observed particularly in atherosclerosis [22], 
type 2 diabetes [23], inflammatory bowel disease [24], in synovial 
fluid from rheumatoid arthritis patients [25], as well as in kidneys 
from both diabetic nephropathic and glomerular disease patients 
[26]. The first clinical trial of low dose heparin (in combination) 
dates back to the 1960s, followed in 1971 by long term high dose 
heparin in chronic glomerular nephritis [26]. The use of heparin and 
glycosaminoglycans as potential anti-complement agents in renal 
dysfunctions has been hypothesized [27].
2.3. Anticancer activity of heparin and LMWHs
The inhibitory activity of heparin on the growth of transplanted 
tumour tissues was first reported in 1930 [28]. Heparin and LMWHs 
have shown “in vivo” inhibitory activity in several experimental 
models. Their anti-metastatic activity seems to be based mainly on 
interference with the spreading of tumour cells in the blood and 
inhibition of angiogenesis, selectins as well as heparanase [29] and 
tissue factor (TF) over-expressed during inflammation and in the 
presence of aggressive cancers [30]. A recent report indicated an 
additional chemo-sensitizing activity of heparin through inhibition 
of P-glycoprotein- mediated multidrug resistance [31]. The results 
of “in vitro”, “in vivo” studies and clinical trials have been reviewed 
[29,32–34]. Retrospective evaluation of early clinical trials indicated 
that heparin can provide survival benefits to cancer patients 
compared to other anti-thrombotics [32]. The inhibition of clots 
associated with tumour tissues, by heparin and LMWHs can increase 
accessibility of anticancer drugs and the efficacy of chemotherapy, 
but also induces drug resistance in some cases [35,36]. LMWHs are 
considered by current clinical guidelines to be the drug of choice 
for antithrombotic treatment in cancer patients. Adjunct therapy 
in small cell lung cancer patients with or without Bemiparin 
compared to chemo-radiation showed increased response rates and 
median survival times [37]. Comparable results were obtained with 
Dalteparin combined with chemotherapy in non-small cell lung 
cancer patients when compared with chemotherapy alone [38]. 
Other positive effects were observed in terminal cancer patients 
treated with Nadroparin or Dalteparin, as well as with Enoxaparin 
combined with chemotherapy in pancreatic cancer patients [29]. An 
updated systematic review and meta-analysis of randomized trials 
on survival of cancer patients treated with LMWHs has been reported 
[39]. A retrospective study on small cell lung cancer patients treated 
with heparin showed overall beneficial effects even when using 
different commercial heparin preparations [38]. Their intrinsic 
heterogeneity, despite their comparable anticoagulant activity, was 
probably one of the major factors behind some irreproducible or 
conflicting results. In this context the seminal report of J. Folkman 
et al. “Angiogenesis inhibition and tumour regression caused 
by heparin or a heparin fragments in the presence of cortisone” 
[40]. Following a preliminary selection from commercial heparins 
for their anti-angiogenic activity, the most active heparin found 
was “Panheprin” from Abbot that was discontinued soon after. 
Difficulties in reproducing the results using different commercial 
heparins interrupted this line of research [42]. Beneficial effects 
observed in anecdotal and clinical trials are reported in Table 1.
2.4. Other experimentally investigated activities
After an early report [56] on the “in vitro” inhibition of Herpes 
simplex virus, in the mid-1980s, the potential for heparin and sulfated 
polysaccharides, to inhibit HIV in vitro [57], were investigated. 
Other reports showed the broad spectrum of “in vitro” activity of 
heparin on a variety of RNA and DNA viruses [58,59]. As for other 
therapeutic applications, anticoagulant activity limited doses, 
poor pharmacokinetics and the poor oral absorption of heparin 
were the major drawbacks to further developments. Heparin can 
exert neuroprotective effects in some models of neurodegenerative 
diseases inhibiting apoptotic processes [60]. Table 2 shows some 
other “in vitro” and “in vivo” activities of heparin that have been 
investigated.
2.5. LMWHs, ultra LMWHs and related oligosaccharides as nephro- and 
neuroprotective agents
Experimental and clinical studies in patients with proteinuric 
glomerulonephritis showed benefit by oral treatment with 
sulodexide, a mixture of LMW heparin and dermatan sulfate in a 
Table 1
Heparin: anecdotal* and clinical trials
Target References
Acute respiratory distress syndrome* [5,42]
Allergic rhinitis [43]
Antimalarica [44]
Antiphospholipid syndrome [45]
Asthma and bronchial constriction [5,13]
Cardioversion of atrial fibrillation [46]
Cardiopathies [47]
Chronic obstructive pulmonary diseases [5]
Cystic fibrosis [18,48]
Glomerulonephritis [26]
Hyperlipemias [49]
Inflammatory bowel diseases [5,29,50]
Mucolytic agent (Inhaled) [51]
Nervous system protection by radiation  [52]
Rheumatoid arthritis [5,53]
Severe sepsis [54]
Tissue repair and wound healing [5]
Vasoprotection  [55]
a Heparin, inhibiting and reversing cytoadherence and rosetting of Plasmodium 
falciparium infected erythrocytes “in vitro”. Tested from 1967 in severe malaria 
clinical trials, after some overall promising outcomes, were discontinued due to 
severe intracranial bleeding [44]
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4:1 weight ratio [26]. Clinical trials of parental LMHWs and oral 
sulodexide in diabetic nephropathic patients were also reported and 
their beneficial effects correlated principally with their inhibition of 
heparanase and oxidative renal insult [71]. In the early 1990s, clinical 
trials showed that “Ateroid” (present in the Italian market until 2014 
as oral and parental formulations), a mixture of glycosaminoglycans 
(GAGs) similar to Sulodexide, may have improved the cognitive 
function of patients with various degenerative conditions correlated 
to amyloid diseases, such as Alzheimer’s (AD), Parkinson’s (PD) 
diseases and transmissible spongiform encephalopathy (TSE) 
[60]. In 1998 some heparin oligosaccharides were found able to 
cross the blood-brain barrier and inhibit -amyloid precursor 
protein secretion [72]. Enoxaparin was also found to be active in 
an AD murine model [73]. Enoxaparin and Dalteparin inhibited 
experimental amyloidosis in clinically relevant doses [74]. To avoid 
anticoagulant effects, a mixture of oligosaccharides, named C3 or 
Neuroparin, prepared by -irradiation of high molecular weight 
heparin, showed neuroprotective effects in AD experimental models, 
also by the oral route [60].
2.6. Other investigated activities of LMWHs
Following randomized applications in vitreoretinal surgery 
[75] LMWHs have been used alone [76] or in combination with 
5-fluoro-uracil [77], to mitigate the high risk of post-operative 
vitreoretinopathies, with significant improvement. As recently 
reviewed [78] in other clinical trials there was no statistical 
difference in the primary outcome, showing a narrow spectrum of 
experimental activity compared to heparin. In another recent review 
with meta-analysis, heparin and derivatives showed positive effects 
in cataract surgery [13]. LMWHs compared with heparin, showed 
more benefit as nephro- and neuroprotective agents. Other activities 
are listed in Table 3.
3. Chemical derivatives of heparin and LMWHs
The majority of biochemical, pharmacological and clinical 
investi gations of heparins reported here, have employed heparin 
preparations manufactured as anticoagulants that can induce, 
in other therapeutic applications, side effects such as bleeding. 
This drove the investigation into the properties of heparin chains 
with no-affinity for AT and of chemically modified heparin with 
reduced anticoagulant activity. More selective approaches have 
been considered for both heparin fractions, with reduced AT affinity 
and anticoagulant activity, as well as rationally designed heparin 
derivatives targeting more specific interacting proteins. Comparison 
of the peculiar heparin sequences with libraries of amino acid 
sequences of heparin binding proteins may allow the prediction and 
identification of more specific interactions and new leads [85,86].
3.1. Sulfation degree modifications
Although the highly sulfated sequences of heparin show protein 
high-affinity binding, some of the sulfated groups can be compatible, 
but are not necessary for certain interactions. Selective desulfation 
can avoid or reduce heparin anticoagulant activity, by removing 
essential sulfated groups from the antithrombin binding region 
(ATBR) and induce selectivity among different protein targets. 
Similar results can be achieved by introducing sulfated groups in 
un-natural positions inducing conformational changes to impair 
ATIII binding.
Early chemical modifications included selective O-acylation 
in 1947 and N-desulfation in 1958 [87]. N-desulfated heparin, 
named “heparamine”, showed reduced anticoagulant activity, 
experimental beneficial effects in preventing hepatic and renal 
damage by ischemia and reperfusion, as well as in inhibiting 
angiogenesis and experimental metastatic gastric cancer [88]. 
Structural modifications and structural activity relationship studies 
were mainly targeted towards inflammation [5], angiogenesis, 
cardiovascular and pulmo nary diseases [11], metastasis [89] as 
well as Alzheimer’s disease [90] and cerebral malaria [91]. The 
last two reports demonstrated the activity of N-desulfated-N-
acetylated heparin (named heparide) and LMWHs. These and 
some N-acyl analogues showed beneficial effects in inflammation 
myocardial ischemic and reperfusion injury [5], inhibitory 
activity of angiogenesis and metastasis [89] in a broad spectrum 
of experimental models. An oversulfated LMWH preparation was 
found beneficial in an iron restricted anaemia model through 
inhibition of the peptide hormone Hepcidin [68]. Various types of 
derivatives, chemical processes, some biological interactions and 
activities are reported in dedicated reviews [87,89,92,93]. While 
the early structurally defined heparin binding to AT and thrombin 
supported the search of new anticoagulants and antithrombotics, 
only a few of the heparin interactions with the multitude of 
proteins involved, for example in inflammation [5], angiogenesis, 
metastasis and cancer [94] as well as atherosclerosis (LDL) 
[95] have been fully investigated to date. Owing to the intrinsic 
heterogeneity of heparin, which is sometimes increased by side 
reactions resulting from the difficulties of chemical handling and 
lack of selectivity, gave rise up to the 1990s to the development of 
a few leads and approved drugs. To our knowledge, Hirudoid, an 
oversulfated heparin is still on the market as a local vasoprotective 
formulation [93]. An O-butanoyl heparin derivative was found 
active in lung cancer experimental models [96]. Clinical trials 
of 2-O, 3-O desulfated heparin (ODSH), in combination with 
chemotherapy, showed benefits in untreated metastatic pancreatic 
cancer patients [97]. In the early 1990s another ODSH formulation 
was developed for the treatment of chronic obstructive pulmonary 
disease, but discontinued in 1994 [5].
Table 2
Heparin activity investigated “in vitro” and “in vivo”
Target References
Allergic encephalomyelitis [5]
Auto-immuno diseases [61]
Anti-complement [29,62,63]
Anti-atherosclerosis [64]
Diabetic nephropathies [26,65]
Emphysema [66,67]
Iron-restricted anemia [68]
Neuroprotection [60]
Osteogenesis [69] 
Periodontal diseases [70]
Table 3
Other clinical and experimental activities of LMWHs
Target Compound References
Asthmaa IVX0142 (Sulfate disaccharide) inhaled [79]
Cystic fibrosisb  [80]
Emphysemab Fraxiparine [81]
Hematopoiesic  [82]
Obstetricsc,e Dalteparin [83]
Retinal angiogenesisc Suloparoidd [84]
Ulcerative colitisc LMWHs [9]
a Anecdotal trial; b experimental models; c clinical trials; d LMW heparan sulfate; 
e shorter human labor.
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3.2. Glycol-split heparins (gs-heparins)
Periodate oxidation has been applied to obtain non-anticoagulant 
heparins without impairing other biological activities and inducing 
reduced side reactions, i.e. depolymerization, and preserves both 
the pattern and degree of sulfation [98,99]. Periodate can selectively 
oxidize adjacent carbons bearing unsubstituted hydroxyl and /or 
amino groups [100], leading, in heparins, to the splitting of C(2)-C(3) 
bonds of un-sulfated uronic acids including the glucuronic acid, 
within the ATBR, essential for high anticoagulant activity [101]. 
Subsequent borohydride reduction leads to the “glycol-split” (gs) 
derivatives, also named reduced oxyheparins (ROHs), as shown in 
Fig. 1 Under well-controlled conditions, the first intermediate oxy-
heparin and final gs-heparin samples, that preserved the original 
Mws, were fully-characterized in terms of their chemical-physical 
properties and “in vivo” anti-lipemic activity, as well as residual 
anticoagulant activity in 1986 [99]. The increase of chain flexibility, 
induced by gs-residues and the ability to maintain the principal 
biological interactions of heparin has led in the last thirty years to a 
number of active gs-heparins differing in size and extent of glycol-
splitting, shown in Table 4.
Among the gs-heparins under development, only SST0001 
(N-desulfated-N-acetyl gs-heparin) shows a size comparable to 
that of high molecular weight heparin. This inhibits heparanase, 
angiogenesis, downregulates FGF-2, HGF, MMP9 and PDGF 
abrogating PDGF receptor tyrosine phosphorylation. The heparanase 
role in radiation-enhanced invasiveness of pancreatic carcinoma 
is abolished by SST001 “in vivo” [102]. The SST0001 inhibition of 
heparanase mediated signaling overcame the resistance in Lapatinib 
resistant brain metastatic breast cancer cells [103]. An additional 
heparanase mediated pathway inhibited by SST0001 “in vitro” is 
the stimulation of chondrogenesis up-regulated by heparanase 
in human ectopic cartilage and possibly involved in hereditary 
multiple exostoses, a pediatric skeletal disorder characterized by 
benign cartilaginous tumours [104]. SST0001 was found effective in 
several tumour xenografts of hematologic (myeloma) [105] and solid 
(sarcoma) malignancies [106, 107]. Roneparstat has been tested in a 
Phase I trial for advanced myelomas and patients are being enrolled 
for a Phase II trial.
All the other gs-heparins including those in clinical trials show 
low or very low Mw. Vasoflux, obtained by glycol splitting of a LMWH, 
afforded anticoagulant activity independent of AT and HCII [108]. 
Addition of Vasoflux to streptokinase and Aspirin in a randomized 
clinical trial for prevention of acute myocardial infarction, did not 
improve the response compared to heparin [109].
M402, a gs-LMWH, inhibits heparanase, growth factors involved 
in angiogenesis, other pathways and metastasis in orthoptic murine 
carcinoma models [110]. Since June 2005, Nocuparanib has been a 
candidate in Phase II clinical trial for metastatic pancreatic cancer in 
combination with chemotherapy. Clinical trials of DF01 (Tafoxiparin) 
for the prevention and treatment of protracted labour are ongoing 
[111]. DFX -232 and Sevuparin, as inhibitors of red cell aggregation, 
known as rosetting, arising from “Plasmodium falciparium” infection, 
are under clinical trial as anti-malarials and for prevention of 
vascular occlusion by sickle red cells in severe hereditary anaemia 
[112].
3.3. Heparin oligosaccharides
The biosynthetic structural heterogeneity of heparin chains, 
further enhanced by chemical treatments during manufacture and 
purification, make their sequence analysis very difficult. To prepare 
a library of pure oligosaccharides from natural heparin is another 
very challenging task. Nevertheless hundreds of oligosaccharide 
have been isolated over the years, mainly by enzymatic or nitrous 
acid partial depolymerization, and tested for a broad range of 
biological activities and protein interactions. Through a recent 
rational approach, active oligosaccharides from hexa- up to 
dodecasaccharides have been chemo-enzymatically prepared 
starting from the structural homogeneous bacterial polysaccharide 
K5 [129] using recombinant versions of the heparin biosynthesis 
enzymes [130].
4. Heparin conjugates and orally delivery systems
An oxy-heparin preparation, (from heparin periodate oxida-
tion) was linked through the newly formed aldehyde groups 
to polystyrene to provide the conjugate NAC-HCPS, inhibiting 
angiogenesis and metastasis in experimental models [131], the 
same activity shown by a conjugate of Fraxiparin (LH17), through a 
diaminoethylene bridge with taurocholate [132]. Other conjugates 
have been designed as delivery systems for anticancer drugs, such 
as Doxorubicin [133]. An orally active 6-O-desulfated Nadroparin 
conjugate with deoxycholate (6ODS-LHbD) was found to inhibit 
angiogenesis and bone destructive arthritis in experimental models 
[134]. Ignoring anecdotal reports, orally active heparin formulations 
have been the aim of formulation scientists and clinicians for some 
time. A variety of approaches have been summarized recently [135]. 
To mention one instance, N-[8-(2-hydroxyl benzoyl)amino]caprilate 
(SNAC) was selected as an oral enhancing delivery agent for heparin. 
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Fig. 1. Simplified formula of representative ATBR- containing chain of porcine mucosal heparin (a) and the corresponding gs derivative (b) obtained by periodate oxidation/
borohydride reduction. I = Iduronic acid, A= Glucosamine, G = glucuronic acid, gs = glicol-split, ATBR = antithrombin binding region.
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The efficacy of two liquid formulations in a thromboprophylaxis 
Phase III clinical trial, in comparison with standard s.c. LMWH 
therapy, did not show significant benefits [136].
5. Conclusion
Up-dating the non-anticoagulant activities of heparins has not 
been an easy task considering the number of reports disclosing 
their new roles in signaling and pathways involved in a variety of 
pathologies. In competition with chemo-enzymatic approaches, 
natural heparins, may improve their chances. The manufacture of 
pharmaceutical grade heparin has been optimized for anticoagulant 
efficacy which mainly represents the principal side effect for other 
applications. Given the heterogeneity of raw heparin chains, it 
is probable that sequences and chains better involved in other 
applications may be lost but, also selected in processing natural 
heparins. In the future, selection based on size or lack of AT-binding, 
followed by compositional and structural characterization would 
provide more useful and rational preparations preserving particular 
sequences, for new non-anticoagulant leads and applications.
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